Home Health Care Regeneron and Teva team up to develop and market pain drug

Regeneron and Teva team up to develop and market pain drug

SHARE

Westchester-based Regeneron Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd., an Israeli producer of generic medicines headquartered in Jerusalem, recently announced a global agreement to develop and commercialize fasinumab, an investigational antibody against nerve growth factor, or NGF, that is in clinical trials by Regeneron as a treatment for osteoarthritis pain and chronic low back pain. Under the…

This content is for Westfair Online members only. Please to view this content. Become a member by Registering Here. If you would prefer to start with a 12 week free trial, Click Here.

Non members are only allowed 10 clicks per month

Print Friendly